OpenEvidence Funding History

OpenEvidence operates an AI-powered medical evidence search platform for clinicians. Its focus is on helping clinical users find medical information, placing evidence retrieval at the center of the product.

Company Overview

  • Healthcare
Official Website

OpenEvidence Funding Timeline

  1. Reported Sep 30, 2026

    Funding Round

    US$250 million

    Source · forbes.com ↗
  2. Jan 21, 2026

    Series D

    $250M · $12B valuation

    Led by Thrive Capital, DST Global.

    Source · cnbc.com ↗
  3. Oct 20, 2025

    Series C

    US$200 million

    Led by GV.

    Source · nytimes.com ↗
  4. Jul 15, 2025

    Funding Round

    US$210 million

    Source · prnewswire.com ↗
  5. Feb 19, 2025

    Series A

    US$75 million

    Led by Sequoia Capital.

    Source · maginative.com ↗

OpenEvidence Products

  • OpenEvidence

    Medical evidence search platform for clinicians, aggregating medical literature, clinical guidelines, systematic reviews and drug interaction checks.

    Official Website ↗
    Details and Sources
    Status: activeReviewed: 2026-10-14

FAQ

How does clinical evidence search differ from an AI scribe?

Evidence search helps retrieve and interpret medical literature. A scribe documents an encounter. They address different tasks even when both use language models.

Does a cited medical answer remove the need for clinical judgment?

No. A clinician still needs to assess the evidence, patient context, applicability and limitations of the underlying studies.

Why does literature currency matter in medical question answering?

Guidelines and research findings can change. Publication dates, evidence updates and whether an answer reflects newer results affect its usefulness.

Does OpenEvidence’s funding validate every answer it produces?

No. Financing is separate from evaluating answer quality and clinical suitability. Individual claims need support from the cited evidence.

How should conflicts between medical sources be assessed?

Compare study design, population, outcomes and the strength and date of recommendations rather than relying on the number of citations alone.

What distinguishes literature access from permission to reuse it?

Reading access, text-mining rights and redistribution rights can have different terms. A searchable article is not automatically licensed for every downstream use.